| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 1.49 | 2.6% | 8.8% |
| Total Income | 1.49 | 2.6% | 8.8% |
| Expenditure | 17.93 | 7.4% | 18.2% |
| PBT | — | ||
| Net Profit | -24.88 | 29.7% | 68.8% |
| OPM | — | ||
| NPM | — | ||
| EPS | -0.07 | 16.7% |
Ocugen Reports Q2 2026 Financial Results and Business Updates
06 Aug 2026 · 6 Aug, 6:03 pm
Summary
Ocugen, Inc. reported its second quarter 2026 financial results and provided a comprehensive business update. The company highlighted significant progress across its gene therapy pipeline, including FDA clearance for the OCU410 Phase 3 trial and RMAT designation. Financially, Ocugen closed a $130 million convertible senior notes offering, extending its cash runway into 2028. Management expressed optimism about multiple catalysts through 2028, focusing on creating long-term value for patients and shareholders.
Key Highlights
- 1
Ocugen received FDA clearance to initiate the OCU410 Phase 3 trial for geographic atrophy (GA), a significant step towards addressing dry age-related macular degeneration.
- 2
The company secured Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for OCU410, paving the way for priority review and accelerated approval.
- 3
A binding term sheet was signed with Roots Pharmaceutical for an exclusive license of OCU400 in the Middle East and North Africa (MENA) region, potentially worth up to $255 million in sales milestones.
- 4
Ocugen successfully completed OCU400 Process Performance Qualification (PPQ) batches, supporting the Biologics License Application (BLA) and commercial launch supplies.
- 5
The company closed a $130.0 million convertible senior notes financing, extending its cash runway into 2028.
- 6
Enrollment was completed ahead of schedule for the pivotal Phase 2/3 GARDian3 trial evaluating OCU410ST in patients with Stargardt disease.
- 7
Ocugen reported total operating expenses of $17.9 million for the three months ended June 30, 2026, compared to $15.2 million for the same period in 2025.
Management Comments
Shankar Musunuri
The second quarter of 2026 marked a pivotal inflection point for Ocugen. We closed $130 million convertible senior notes financing, extending our cash runway into 2028, and signed a binding term sheet for exclusive license of OCU400 in retinitis pigmentosa across the Middle East and North Africa region. Ocugen is a leading gene therapy company, focused on vision loss diseases with significant unmet medical needs, with multiple catalysts through 2028 across three distinct retinal disease indications. As we advance toward key data milestones in the first half of 2027, we remain focused on creating long-term value for our patients and shareholders.
Informational and educational content only. Not investment advice.